NKGen Biotech appoints Michael Klowden and Kathleen Scott as directors

NKGen Biotech, Inc.

Michael Klowden appointed Class II director until 2025 annual meeting; also joins Audit and Compensation Committees and chairs N&CG Committee.
Kathleen Scott appointed Class III director until 2026 annual meeting; chairs Audit and Compensation Committees and serves on N&CG Committee.
Both directors will receive deferred non-employee director compensation, paid when Company meets funding goals.
No arrangements or related transactions exist between new directors and Company per Reg S-K Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kathleen Scott

Director

NKGen Biotech, Inc.

Effective: 2024-10-03
Filed: October 4, 2024, 7:59 PM ET

The Board following a recommendation from the N&CG Committee, also unanimously elected to have Kathleen Scott fill, effective immediately, the Class III director vacancy created by her resignation

Appointed

Michael Klowden

Director

NKGen Biotech, Inc.

Effective: 2024-10-03
Filed: October 4, 2024, 7:59 PM ET

On October 3, 2024, the Board of Directors (the “Board”) of NKGen Biotech Inc. (the “Company”), following a recommendation from the Nomination and Corporate Governance Committee (the “N&CG Committee”), unanimously elected to have Michael Klowden fill, effective immediately, the Class II director vacancy

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Kathleen Scott was elected as Director at NKGen Biotech, Inc..

Action: elected
Role: Director

Exact text from the filing

The Board following a recommendation from the N&CG Committee, also unanimously elected to have Kathleen Scott fill, effective immediately, the Class III director vacancy created by her resignation

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 1.0

Michael Klowden was elected as Director at NKGen Biotech, Inc..

Action: elected
Role: Director

Exact text from the filing

On October 3, 2024, the Board of Directors (the “Board”) of NKGen Biotech Inc. (the “Company”), following a recommendation from the Nomination and Corporate Governance Committee (the “N&CG Committee”), unanimously elected to have Michael Klowden fill, effective immediately, the Class II director vacancy

View on SEC.gov

Source: SEC EDGAR

accession 0001213900-24-085185

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.